Gemigliptin, a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, was able to relieve hepatic steatosis and insulin resistance by suppressing LECT2 expressions involved in increased AMPK phosphorylations in HFD‐fed mice.31 This evidence concerns the gene LECT2 and fatty liver disease.